TMO Stock Recent News

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its innovative manufacturing center of excellence facility in Mebane, N.C. The new 375,000-square-foot carbon neutral site will be capable of producing at least 40 million laboratory pipette tips per week, helping to ensure that life-saving medicines and therapies continue to be developed and produced in the U.S. for decades to come. “As a global leader in li.

An analyst launched coverage of Thermo Fisher Scientific (TMO 2.15%) after market close on Monday, and the stock was experiencing a little pop the following day as a result. On Tuesday, it closed more than 2% higher in price, contrasting well with the 0.6% slide of the benchmark S&P 500 (^GSPC -0.59%).

Could Thermo Fisher Scientific Inc. TMO be the unsung hero of the biopharma sector's future? While its stock performance has recently lagged, analysts are betting on a major turnaround driven by strategic acquisitions and robust growth potential.

Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.

The Investment Committee give you their top stocks to watch for the second half.

Revenue growth is accelerating, led by pharma/biotech momentum and bioproduction demand. The medium-term margin outlook is positive with cost cuts, AI-driven efficiencies, and lapping of tariff headwinds starting next year. Valuation attractive vs. history and peers, supporting potential re-rating.

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumors harbor human epi.

Thermo Fisher is emerging from a challenging period with solid fundamentals, strong cash flow, and renewed growth, making it undervalued by the market. Recent earnings showed organic growth, margin expansion, and raised guidance, signaling a return to normalcy and operational strength. Valuation models indicate 15–48% upside, driven by recurring revenues, loyal customers, and potential for multiple expansion as confidence returns.

I reiterate my Buy rating on Thermo Fisher Scientific Inc., with a fair value estimate of $568 per share, reflecting its undervalued stock price. Q2 FY25 results showed early signs of market recovery, with 2% organic revenue growth and raised full-year revenue and EPS guidance. Pharma and biotech segments are recovering, but academic and government markets face headwinds from U.S. funding uncertainties and policy risks.